down arrow

Moleculin Biotech, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US60855D2009
USD
7.71
1.08 (16.29%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Lisata Therapeutics, Inc.
Eiger BioPharmaceuticals, Inc.
Lipocine, Inc.
Scorpius Holdings, Inc.
Mangoceuticals, Inc.
NanoViricides, Inc.
Edesa Biotech, Inc.
Moleculin Biotech, Inc.
Mustang Bio, Inc.
Virios Therapeutics, Inc.
Aprea Therapeutics, Inc.
Why is Moleculin Biotech, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is Moleculin Biotech, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Moleculin Biotech, Inc.
-88.05%
-0.36
255.25%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-7.15%
EBIT to Interest (avg)
-24.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-7.59
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.88%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.47
EV to EBIT
-0.07
EV to EBITDA
-0.07
EV to Capital Employed
-0.25
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-3695.30%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -21.33 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

OPERATING PROFIT(Q)

Highest at USD -5.69 MM

EPS(Q)

Highest at USD -0.49

-20What is not working for the Company
ROCE(HY)

Lowest at -503.8%

CASH AND EQV(HY)

Lowest at USD 15.27 MM

DEBT-EQUITY RATIO (HY)

Highest at 99.61 %

PRE-TAX PROFIT(Q)

Lowest at USD -17.25 MM

NET PROFIT(Q)

Lowest at USD -17.25 MM

Here's what is working for Moleculin Biotech, Inc.
Operating Cash Flow
Highest at USD -21.33 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit
Highest at USD -5.69 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

EPS
Highest at USD -0.49
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Moleculin Biotech, Inc.
Pre-Tax Profit
At USD -17.25 MM has Fallen at -186.77%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -17.25 MM has Fallen at -186.77%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Pre-Tax Profit
Lowest at USD -17.25 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -17.25 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv
Lowest at USD 15.27 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at 99.61 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."